Combining Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes

**What is the purpose of this clinical trial?**

This study tests targeted treatments for people with advanced non-small cell lung cancer that has certain changes (mutations) in both the EGFR and MET genes. Finding these changes gives your doctor more information about what is causing the cancer to grow and how to treat it.

Targeted drugs fight specific changes in cancer cells that help tumors grow and spread. Treatment in this study targets EGFR and MET gene changes with 2 drugs, osimertinib and capmatinib.

Researchers want to find out if adding another drug called ramucirumab can improve treatment with osimertinib and capmatinib. Combining all 3 drugs might be better at fighting the cancer.

**This trial is set up to find out:**

- If adding the drug ramucirumab to osimertinib and capmatinib lowers the chance that the cancer will spread or get worse
- How safe the study treatments are for people with advanced non-small cell lung cancer

**Why is this trial important?**

Some people who start treatment for cancer with an EGFR gene change develop a MET gene change. MET gene changes can cause an EGFR targeted drug to stop working. Research on targeted drugs is quickly advancing, and this trial is a chance to improve treatment for cancer that has both gene changes.

There is evidence that combining EGFR and MET targeted drugs is safe and works to fight cancer. The Food and Drug Administration (FDA) has separately approved osimertinib and capmatinib to treat advanced non-small cell lung cancer.

There is also evidence that adding ramucirumab could improve treatments that use EGFR and MET targeted drugs. Ramucirumab has been approved by the FDA for use with other drugs for advanced non-small cell lung cancer.
Who can be in this trial?

This trial is for adults, age 18 or older, with non-small cell lung cancer that is stage 4 or has come back after treatment.

**This trial is for people who:**
- Have cancer with **EGFR** and **MET** gene changes
- Have cancer that has gotten worse after treatment using the **EGFR** targeted drug, osimertinib

**This trial is not for people who:**
- Have another cancer that may make it unsafe to get treatment in this study
- Have serious heart problems
- Have an active HIV infection
- Are pregnant

Talk with your doctor to learn more about who can join this trial.

What treatments will I get?

Each drug in this study targets cancer cells in a different way:
- Osimertinib (Tagrisso) targets **EGFR** gene changes
- Capmatinib (Tabrecta) targets **MET** gene changes
- Ramucirumab (Cyramza) blocks tumors from forming new blood vessels (pathways that carry blood to the tumor)

If you join this study, you will be randomly assigned to one of 2 study groups.

<table>
<thead>
<tr>
<th>Group 1:</th>
<th>Group 2:</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="pill+pill.png" alt="Osimertinib and Capmatinib" /></td>
<td>osimertinib + capmatinib</td>
</tr>
<tr>
<td><img src="infusion.png" alt="Ramucirumab" /></td>
<td></td>
</tr>
</tbody>
</table>

Your doctor will not have control over which group you will be assigned to. This helps make sure the study results are fair and reliable.
Thank you!
When you join a clinical trial, you’re moving cancer medicine and patient care forward.